Pankreatix

Pankreatix is a pre-clinical stage biotechnology company focused on developing first-in-class small molecule therapeutics for the treatment of pancreatitis. The company's lead program targets the premature activation of trypsin within the pancreas, a key driver of organ damage in both acute and chronic forms of the disease. By inhibiting specific serine proteases, Pankreatix aims to provide the first targeted pharmacological intervention for a condition that currently relies primarily on supportive care. The company is leveraging research from the University of California, San Diego to address significant unmet needs in gastrointestinal health.